- Committed to help inventors, contribute to S’pore’s biotech habitat
- Announced a US$ 14.5 million funding from Celadon Partners and ClayvstBio
NSG BioLabs, Singapore’s company of biotech co- working labs and workplace space has announced partnerships with Enterprise Singapore, the Singapore government agency championing enterprise development, and Merck, a leading science and technology company, to boost the biomedical landscape by providing needed resources for as funding, expertise and networks to advance startup research and development.  ,
In a statement, the company said it has also concluded a US$ 14.5 million ( RM68.7 million ) financing round led by Celadon Partners, an Asian private equity firm, and ClayvstBio, a life science investor and venture builder set up by Temasek to accelerate the commercialisation of breakthrough ideas to health impact.  ,
It added that these achievements reaffirm the company’s power and expertise in providing higher- quality, nicely- managed, and turnkey Biosafety Level 2 accredited laboratory and office spaces. Also, these milestones underscore NSG BioLabs as an ecology precursor, providing value- include services and networks, which are critical in driving technological innovation and business growth.
Since 2019, NSG BioLabs has been assisting innovators in creating effective solutions in the health, medical, agrifood, and professional biotechnology sectors, working in areas like as precision medicine, nucleic acids, AI- enabled drug discovery, and artificial biology. The company has assisted over 40 businesses as residents with what it claims to be the biggest co-working biotech laboratory and office footprint in Singapore.  ,
The company’s current residents include numerous multi-billion-dollar corporations as well as numerous promising startups that have achieved significant success. The startup residents have already established hundreds of jobs and successfully raised nearly US$ 400 million ( RM1.9 billion ) in funding.  ,
NSG BioLabs, the company’s CEO and founder, Daphne Teo ( pic ), expressed her support for innovators and how proud of its contribution to Singapore’s expanding biotech ecosystem. We hope to encourage greater collaboration among other stakeholders to benefit the biotech industry in Singapore and the Asia-Pacific region, she said.” Our partnerships with EnterpriseSG and Merck demonstrate the importance of a collaborative spirit.”
” We are thankful for the recognition from our investors, Celadon Partners and ClavystBio, and look forward to further empowering our residents in their innovation efforts through expanded facilities, enhanced value- add offerings, and greater exposure to valuable industry networking and mentorship experiences”, Teo said.
NSG BioLabs has been part of EnterpriseSG’s Startup SG Accelerator programme since 2019. In order to accelerate the development and commercialization of such deep tech solutions, the company announced a new partnership with EnterpriseSG to invest in and nurture more high-potential biotech startups. In particular, the company expanded support for those with promising innovations in fields like precision medicine.
Dr Clarice Chen, director of Healthcare and Biomedical, EnterpriseSG stated that Singapore’s biotech landscape has evolved significantly, with a burgeoning community of global startups and doubled healthtech deals in 2023. By providing patient capital, infrastructure, and expertise, EnterpriseSG will continue to collaborate with industry partners like NSG BioLabs to advance the development of novel deep tech innovations like AI-enabled platforms and targeted therapies. This will strengthen Singapore’s edge in precision medicine and revolutionise healthcare delivery”, she added.
The newly acquired funds from Celadon Partners and ClavystBio will be used to improve its products and services and build additional facilities to meet the growing demands of biotech startups and multinational companies in Singapore and Southeast Asia, according to NSG BioLabs, in order to further its mission of supporting biotech innovators.
We are confident that NSG BioLabs ‘ innovative co-working model will provide compelling solutions to biotech startups and companies in the Southeast Asian region given the sector’s significant growth being driven by healthcare needs. NSG BioLabs ‘ commitment to enabling businesses to quickly track their research and development efforts is commendable, according to Donald Tang, managing partner at Celadon Partners.
Meanwhile, Khoo Shih CEO ClavystBio said, the company is excited to foster the growth of Singapore’s life science ecosystem through its support of NSG BioLabs, and its resident startups. ” This investment reinforces ClavystBio’s mission to accelerate breakthrough science into health impact through venture building, and strategic partnerships”, he said.  ,
NSG BioLabs cultivates mutually beneficial relationships between its residents and other important parties as a significant platform in the area with a proven and expanding scale. The company has partnered with Merck to give its residents special terms for Merck’s reagents and life sciences equipment in order to further enable their residents to develop, grow, and scale up. Additionally, the partnership grants you preferential access to biopharma processing expertise and advice on how to increase production.